Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 120 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Platinum-Doublet Chemotherapy Clear all
Recruiting Phase 2 Interventional

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

NCT06463665
View directory record Official record
Conditions
Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
Interventions
Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel
Biological · Drug
Lead sponsor
Genelux Corporation
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
15
States / cities
Bullhead City, Arizona • Clermont, Florida • Coral Springs, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 23, 2026, 1:10 AM EDT
Recruiting Phase 3 Interventional

Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

NCT07777822
View directory record Official record
Conditions
NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC, Non-Squamous Non Small Cell Lung Cancer, Lung Cancer (NSCLC), Metastatic NSCLC - Non-Small Cell Lung Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer
Interventions
zoldonrasib, Placebo, pembrolizumab, pemetrexed + cisplatin /carboplatin
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 23, 2026, 1:10 AM EDT
Terminated Phase 3 Interventional Results available

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

NCT05493501
View directory record Official record
Conditions
NSCLC
Interventions
Aumolertinib monotherapy, Osimertinib monotherapy, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, Nab paclitaxel, Gemcitabine
Drug
Lead sponsor
EQRx International, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Springdale, Arkansas • Hollywood, Florida • Pembroke Pines, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 23, 2026, 1:10 AM EDT
Withdrawn Phase 3 Interventional

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

NCT03417037
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell Lung Cancer
Interventions
BMS-986205, Nivolumab, Chemotherapy
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
19
States / cities
San Diego, California • Fort Myers, Florida • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 23, 2026, 1:10 AM EDT
Completed Phase 3 Interventional Results available

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

NCT01828112
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Ceritinib, Pemetrexed, Docetaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
13
States / cities
Fayetteville, Arkansas • Hollywood, Florida • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 23, 2026, 1:10 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid mouthwash (dexamethasone or equivalent)
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
38
States / cities
Birmingham, Alabama • Anchorage, Alaska • Irvine, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 1:10 AM EDT
Terminated Not applicable Interventional Results available

Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach

NCT02358863
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Modified FOLFOX6, Docetaxel/Capecitabine, Cisplatin/Irinotecan, Cisplatin/Docetaxel, IRI/EPI, EPI/Docetaxel, Irinotecan/Docetaxel, Docetaxel
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 23, 2026, 1:10 AM EDT
Completed Phase 3 Interventional Results available

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

NCT02864251
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Nivolumab, Ipilimumab, Pemetrexed, Cisplatin, Carboplatin
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
18
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 23, 2026, 1:10 AM EDT
Recruiting Phase 2 Interventional

ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer

NCT06902272
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay, Pembrolizumab, Platinum Doublet Chemotherapy
Diagnostic Test · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 23, 2026, 1:10 AM EDT
Recruiting Phase 3 Interventional

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

NCT04267848
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Echocardiography Test, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Observation Activity, Paclitaxel, Pembrolizumab, Pemetrexed Disodium, Questionnaire Administration
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1150
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 747 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 23, 2026, 1:10 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)

NCT05722015
View directory record Official record
Conditions
Metastatic Non-small Cell Lung Cancer
Interventions
Pembrolizumab Formulated with Berahyaluronidase Alfa, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, Nab-paclitaxel, Pembrolizumab, Filgrastim, Pegylated filgrastim
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
9
States / cities
Phoenix, Arizona • Clermont, Florida • Orange City, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 23, 2026, 1:10 AM EDT
Recruiting Phase 2 Interventional

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

NCT06667908
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
JNJ-90301900, Durvalumab, Concurrent Chemo/Radiation Therapy (cCRT), Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin, Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel
Drug · Biological · Radiation
Lead sponsor
Johnson & Johnson Enterprise Innovation Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
La Jolla, California • Farmington, Connecticut • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 1:10 AM EDT
Completed Phase 3 Interventional Results available

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

NCT02477826
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Nivolumab, Ipilimumab, Carboplatin, Cisplatin, Gemcitabine, Pemetrexed, Paclitaxel
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
2,747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
25
States / cities
Mobile, Alabama • San Francisco, California • New Haven, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 23, 2026, 1:10 AM EDT
Completed Phase 3 Interventional Results available

Avelumab in First-line NSCLC (JAVELIN Lung 100)

NCT02576574
View directory record Official record
Conditions
First Line Non-Small Cell Lung Cancer
Interventions
Avelumab, Pemetrexed, Paclitaxel, Gemcitabine, Carboplatin, Cisplatin, Avelumab Weekly
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
21
States / cities
Huntsville, Alabama • Surprise, Arizona • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 23, 2026, 1:10 AM EDT
Recruiting Phase 2 Interventional

Repositioning Immunotherapy in VetArans With Lung Cancer

NCT06275360
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Nivolumab
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
7
States / cities
West Haven, Connecticut • Washington D.C., District of Columbia • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 23, 2026, 1:10 AM EDT
Terminated Phase 2 Interventional Results available

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

NCT06094296
View directory record Official record
Conditions
NSCLC
Interventions
BMS-986315, Nivolumab, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Glendale, California • Clermont, Florida • Orange City, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 23, 2026, 1:10 AM EDT
Withdrawn Phase 2 Interventional

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

NCT02662634
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
AGS-003-LNG, Carboplatin, Abraxane, Alimta, Cisplatin, Taxol, Radiation Therapy
Biological · Drug · Radiation
Lead sponsor
GU Research Network, LLC
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 23, 2026, 1:10 AM EDT
Active, not recruiting Phase 2 Interventional

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

NCT05676931
View directory record Official record
Conditions
Advanced Non-Small Cell Lung Cancer
Interventions
Domvanalimab, Quemliclustat, Zimberelimab, Docetaxel, Platinum-Based Doublet
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • Hollywood, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 23, 2026, 1:10 AM EDT
Suspended Phase 1Phase 2 Interventional

A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

NCT04042116
View directory record Official record
Conditions
Advanced Solid Tumor, Gynecologic Cancer
Interventions
Lucitanib, Nivolumab
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 23, 2026, 1:10 AM EDT
Terminated Phase 2 Interventional Results available

Induction Chemo-Nivo in Unresectable Stage III NSCLC

NCT06003075
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell, Lung Cancer Stage III
Interventions
Nivolumab and Chemotherapy, Nivolumab, Post Induction Surgery, Post Induction XRT
Combination Product · Drug · Procedure + 1 more
Lead sponsor
Ralph G Zinner
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 23, 2026, 1:10 AM EDT
Recruiting Phase 2 Interventional

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT07680764
View directory record Official record
Conditions
Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
Pumitamig, Imzokitug, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Athens, Georgia • Lexington, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 1:10 AM EDT
Terminated Phase 3 Interventional Results available

REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

NCT03515629
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
REGN2810/ipi, REGN2810/chemo/ipi, Pembrolizumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Oct 23, 2026, 1:10 AM EDT
Recruiting Phase 2 Interventional

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

NCT05800587
View directory record Official record
Conditions
Lung Cancer, Small-cell Lung Cancer, Non Small Cell Lung Cancer
Interventions
Carboplatin, Pemetrexed, Paclitaxel, Nab paclitaxel, Docetaxel, Gemcitabine, Etoposide, Irinotecan, Topotecan, Lurbinectedin
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 23, 2026, 1:10 AM EDT
Completed Phase 2 Interventional Results available

Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy

NCT00100932
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
E7389 28 Day Cycle, E7389 21 Day Cycle
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
13
States / cities
Gilroy, California • Ocala, Florida • Baltimore, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2012 · Synced Oct 23, 2026, 1:10 AM EDT